Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this pilot study, finasteride increased testosterone/dihydrotestosterone and progesterone/dihydroprogesterone ratios in normal ovulatory women but did not alter ovulation or gonadotropin secretion.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

This review discusses spironolactone as an effective and potentially safer treatment for androgenic alopecia, particularly when used with minoxidil, but calls for more high-quality clinical trials.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

Spironolactone reduces hair growth in women with unexplained excessive hairiness.

This letter to the editor references a study on using dihydrotestosterone gel before hypospadias surgery but itself contains no new findings.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study found that women with PCOS displayed significantly higher activity of 5alpha-reductase, suggesting an additional role for liver and peripheral tissues in their androgen excess.

This study found that women with PCOS have higher activity of the enzyme 5alpha-reductase, which may contribute to their elevated androgen levels.

This study found that antisense oligonucleotides can significantly reduce androgen receptor expression in cultured human sebocytes and may offer new therapeutic possibilities for androgen-associated skin diseases.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This study found that chronic treatment with EE/LNG in female rats decreased brain concentrations of allopregnanolone, leading to reduced social and sexual behaviors; progesterone administration reversed these effects, except when finasteride was used to block the increase.

This study reported a significant increase in the use of spironolactone for treating acne and hidradenitis suppurativa in female adolescents, noting a 2- to 3-fold rise in prescriptions and suggesting improved tolerance compared to adults, though its efficacy in adolescents is less pronounced.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This study found that the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair count and reduced daily hair shedding in patients with androgenetic alopecia over 16 weeks, although other measures did not differ from placebo.

This article discusses the mechanisms and therapeutic use of antiandrogens, specifically cyproterone acetate and chlormadinone acetate, in gynecological treatments without reporting new clinical results.

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This study suggests that the anticonvulsant effects of deoxycorticosterone in young rats may be mediated by its metabolites and interactions with multiple receptors, including mineralocorticoid and progesterone receptors.

Both treatment combinations improved hair growth similarly and were safe.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.